Notably, by comparing CD8+ TILs in the DC–Lysate and DC–Pool Peptide vaccines (which each contain both melanoma and pericyte/VEC antigens) for their reactivity against B16 tumor cells vs. tumor-derived pericytes/VECs, the resultant TIL repertoires appeared quantitatively balanced (in the case of DC–Lysate vaccines) or slightly skewed towards pericytes/VEC (in the case of DC–Pool Peptide vaccines) (Figure 1E,F). The gene discussed is CD8A; the disease is neoplasm.